Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSRA-196 phase 1/2 study in adults with severe alpha-1 antitrypsin deficiency
NL-OMON61241Phase 2Not yet recruiting
- Sponsor
- Tessera Therapeutics
- Start
- Apr 2026
- Modality
- Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of TSRA-196 in alpha-1 antitrypsin deficiency (AATD) and alpha-1 antitrypsin deficiency emphysema, sponsored by Tessera Therapeutics. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
TSRA-196
03
Conditions
alpha-1 antitrypsin deficiency (AATD)alpha-1 antitrypsin deficiency emphysema
Beyond the preview
Go deeper on NL-OMON61241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61241.